MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antivirals]]
			[[Category:Nucleoside analogs]]
			[[Category:Anti-herpesvirus agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #150

2026-05-23T03:51:56Z

parser-claude batch MedTemplate pre-fill, Top 300 #150

New page

{{MedTemplate
| generic = Acyclovir
| brand = Zovirax
| structure =
| classes = [[:Category:Antivirals|Antiviral]], [[:Category:Nucleoside_analogs|Nucleoside analog]], [[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]]
| uses = <vote slug="genital-herpes-use">Genital herpes (HSV-1/2): treatment and suppression</vote>, <vote slug="herpes-labialis-use">Herpes labialis (oral/topical)</vote>, <vote slug="herpes-zoster-use">Herpes zoster (shingles)</vote>, <vote slug="varicella-use">Varicella in immunocompetent adolescents/adults and immunocompromised</vote>, <vote slug="hsv-encephalitis-use">HSV encephalitis (IV)</vote>, <vote slug="neonatal-hsv-use">Neonatal HSV (IV)</vote>
| starting_dose = Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days
| preparations = 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical)
| fda_max = Indication-specific; high-dose IV regimens for encephalitis or disseminated disease
| pill_id =
| routes = Oral, IV, topical
| onset = Symptom relief within 24-48 hours of starting episodic treatment
| duration = 8 hours per oral dose
| halflife = ~3 hours; significantly prolonged in renal impairment<ref name="zovirax-label">FDA Prescribing Information, Zovirax (acyclovir), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018828s041,019909s029,020089s022lbl.pdf</ref>
| bioavailability = ~20% (oral; valacyclovir prodrug raises this to ~55%)<ref name="zovirax-label" />
| pregnancy = Widely used in pregnancy for HSV/VZV indications; reassuring registry data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="acyclovir-mech-claim">Acyclovir is selectively phosphorylated to acyclovir monophosphate by viral thymidine kinase in HSV/VZV-infected cells, then by host kinases to acyclovir triphosphate, a chain-terminating inhibitor of viral DNA polymerase with markedly higher affinity for the viral than host enzyme.</vote> The viral-kinase-only initial phosphorylation step is the source of selectivity; uninfected cells generate minimal active drug. Dose-adjust by renal function; rare crystalline nephropathy with rapid IV bolus (slow IV infusion mitigates)<ref name="zovirax-label" />. Valacyclovir, the L-valyl ester prodrug, provides higher oral bioavailability and a more convenient dosing schedule for outpatient use.
}}

== References ==
<references />

Acyclovir - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #150